Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Anglo American fully exits Valterra Platinum with $2.5bn share sale

(Sharecast News) - Anglo American has raised $2.5bn from the sale of its remaining stake in Valterra Platinum, fully exiting the South African mining company after its demerger earlier this year.

The company sold 52.2m shares via an accelerating bookbuild offering to institutional investors at a price of ZAR845 a share, generating cash proceeds of ZAR44.1bn.

The transaction followed Valterra's "strong start as a standalone company", according to Anglo chief executive Duncan Wanblad, after a 23% surge in the share price since it was spun off in May.

"We continue to have every confidence in its future as the world's leading integrated value chain producer of PGMs. Valterra is perfectly positioned to benefit from the increasingly attractive structural market dynamics for PGMs," Wanblad said.

Proceeds from what Wanblad called a "responsible separation process" will be used to bolster Anglo's balance sheet, the company said.

The Valterra exit marks a "further step in our portfolio simplification to focus on our world-class positions in copper, premium iron ore and crop nutrients", Wanblad said.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.